Antifungal Drug Development: Targeting the Fungal Sphingolipid Pathway

Fungal infections are becoming more prevalent and problematic due to the continual rise of immune deficient patients as well as the progressive development of drug resistance towards currently available antifungal drugs. There has been a significant increase in the development of antifungal compound...

Descripción completa

Detalles Bibliográficos
Autores principales: McEvoy, Kyle, Normile, Tyler G., Del Poeta, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559796/
https://www.ncbi.nlm.nih.gov/pubmed/32825250
http://dx.doi.org/10.3390/jof6030142
_version_ 1783594942376968192
author McEvoy, Kyle
Normile, Tyler G.
Del Poeta, Maurizio
author_facet McEvoy, Kyle
Normile, Tyler G.
Del Poeta, Maurizio
author_sort McEvoy, Kyle
collection PubMed
description Fungal infections are becoming more prevalent and problematic due to the continual rise of immune deficient patients as well as the progressive development of drug resistance towards currently available antifungal drugs. There has been a significant increase in the development of antifungal compounds with a similar mechanism of action of current drugs. In contrast, there has been very little progress in developing compounds inhibiting totally new fungal targets or/and fungal pathways. This review focuses on novel compounds recently discovered to target the fungal sphingolipids and their metabolizing enzymes.
format Online
Article
Text
id pubmed-7559796
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75597962020-10-29 Antifungal Drug Development: Targeting the Fungal Sphingolipid Pathway McEvoy, Kyle Normile, Tyler G. Del Poeta, Maurizio J Fungi (Basel) Review Fungal infections are becoming more prevalent and problematic due to the continual rise of immune deficient patients as well as the progressive development of drug resistance towards currently available antifungal drugs. There has been a significant increase in the development of antifungal compounds with a similar mechanism of action of current drugs. In contrast, there has been very little progress in developing compounds inhibiting totally new fungal targets or/and fungal pathways. This review focuses on novel compounds recently discovered to target the fungal sphingolipids and their metabolizing enzymes. MDPI 2020-08-20 /pmc/articles/PMC7559796/ /pubmed/32825250 http://dx.doi.org/10.3390/jof6030142 Text en © 2020 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Review
McEvoy, Kyle
Normile, Tyler G.
Del Poeta, Maurizio
Antifungal Drug Development: Targeting the Fungal Sphingolipid Pathway
title Antifungal Drug Development: Targeting the Fungal Sphingolipid Pathway
title_full Antifungal Drug Development: Targeting the Fungal Sphingolipid Pathway
title_fullStr Antifungal Drug Development: Targeting the Fungal Sphingolipid Pathway
title_full_unstemmed Antifungal Drug Development: Targeting the Fungal Sphingolipid Pathway
title_short Antifungal Drug Development: Targeting the Fungal Sphingolipid Pathway
title_sort antifungal drug development: targeting the fungal sphingolipid pathway
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559796/
https://www.ncbi.nlm.nih.gov/pubmed/32825250
http://dx.doi.org/10.3390/jof6030142
work_keys_str_mv AT mcevoykyle antifungaldrugdevelopmenttargetingthefungalsphingolipidpathway
AT normiletylerg antifungaldrugdevelopmenttargetingthefungalsphingolipidpathway
AT delpoetamaurizio antifungaldrugdevelopmenttargetingthefungalsphingolipidpathway

Ejemplares similares